Contineum Therapeutics (CTNM) Competitors $4.62 +0.24 (+5.48%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$4.60 -0.02 (-0.43%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. PHAR, RCKT, ANAB, COGT, LENZ, OPT, BCAX, DNTH, IMNM, and VALNShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Pharming Group (PHAR), Rocket Pharmaceuticals (RCKT), AnaptysBio (ANAB), Cogent Biosciences (COGT), LENZ Therapeutics (LENZ), Opthea (OPT), Bicara Therapeutics (BCAX), Dianthus Therapeutics (DNTH), Immunome (IMNM), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Pharming Group Rocket Pharmaceuticals AnaptysBio Cogent Biosciences LENZ Therapeutics Opthea Bicara Therapeutics Dianthus Therapeutics Immunome Valneva Contineum Therapeutics (NASDAQ:CTNM) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation. Do analysts prefer CTNM or PHAR? Contineum Therapeutics currently has a consensus target price of $24.80, suggesting a potential upside of 436.80%. Pharming Group has a consensus target price of $30.00, suggesting a potential upside of 274.06%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Contineum Therapeutics is more favorable than Pharming Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CTNM or PHAR? Pharming Group received 12 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 67.65% of users gave Pharming Group an outperform vote. CompanyUnderperformOutperformContineum TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesPharming GroupOutperform Votes2367.65% Underperform Votes1132.35% Does the media favor CTNM or PHAR? In the previous week, Pharming Group had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Pharming Group and 2 mentions for Contineum Therapeutics. Pharming Group's average media sentiment score of 1.20 beat Contineum Therapeutics' score of 0.29 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, CTNM or PHAR? Contineum Therapeutics has higher earnings, but lower revenue than Pharming Group. Pharming Group is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M2.39$22.72M-$4.90-0.94Pharming Group$297.20M1.84-$10.55M-$0.17-47.18 Is CTNM or PHAR more profitable? Contineum Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -6.09%. Pharming Group's return on equity of -7.65% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -49.92% -20.52% Pharming Group -6.09%-7.65%-3.82% Do institutionals and insiders hold more shares of CTNM or PHAR? 0.0% of Pharming Group shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryContineum Therapeutics and Pharming Group tied by winning 9 of the 18 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.53M$6.44B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.31%P/E Ratio-0.946.8821.7317.77Price / Sales2.39231.02379.1697.65Price / Cash6.3565.6738.2234.64Price / Book-1.245.916.443.98Net Income$22.72M$142.72M$3.21B$247.44M7 Day Performance15.21%4.33%2.82%1.82%1 Month Performance-38.32%-12.80%-8.67%-6.98%1 Year Performance-70.16%-9.71%11.32%1.49% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics2.1582 of 5 stars$4.62+5.5%$24.80+436.8%-70.0%$119.53M$50M-0.9431Positive NewsGap DownPHARPharming Group2.5625 of 5 stars$8.11+5.5%$30.00+269.9%-21.1%$551.73M$297.20M-31.19280Short Interest ↓Positive NewsRCKTRocket Pharmaceuticals4.6276 of 5 stars$5.19+1.4%$43.00+728.5%-73.3%$545.95MN/A-1.89240News CoveragePositive NewsGap UpHigh Trading VolumeANABAnaptysBio2.559 of 5 stars$17.78-3.9%$35.11+97.5%-4.3%$545.26M$91.28M-2.92100Positive NewsCOGTCogent Biosciences2.4597 of 5 stars$4.58-4.0%$14.43+215.0%-33.1%$543.06MN/A-1.8580Positive NewsHigh Trading VolumeLENZLENZ Therapeutics1.7815 of 5 stars$19.50-7.9%$41.67+113.7%+34.6%$537.09MN/A-4.09110Analyst ForecastNews CoverageHigh Trading VolumeOPTOpthea0.7611 of 5 stars$3.41+7.2%$1.33-60.9%-0.3%$524.84M$87,666.000.008Gap UpBCAXBicara TherapeuticsN/A$9.51-10.0%$36.50+283.8%N/A$518.51MN/A0.0032Analyst ForecastNews CoverageGap DownDNTHDianthus Therapeutics2.0964 of 5 stars$15.61-3.2%$54.33+248.1%-16.5%$517.86M$6.24M-6.2480Positive NewsIMNMImmunome2.5288 of 5 stars$5.88-0.8%$25.14+327.6%-54.5%$511.27M$9.04M-0.7340Positive NewsVALNValneva1.8012 of 5 stars$6.24+4.3%$16.00+156.4%-12.4%$507.07M$169.58M-48.00700Analyst ForecastGap Up Related Companies and Tools Related Companies PHAR Competitors RCKT Competitors ANAB Competitors COGT Competitors LENZ Competitors OPT Competitors BCAX Competitors DNTH Competitors IMNM Competitors VALN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTNM Stock Free CTNM Stock Alerts